scPharmaceuticals Inc., incorporated in 2014, develops a portfolio of transformative pharmaceutical products for subcutaneous delivery. Based on widely used generic drugs that currently require intravenous or intramuscular injections, scPharmaceuticals’ proprietary and innovative products will be administered subcutaneously via the sc2Wear Infusor. This subcutaneous administration avoids material risks and costs associated with the current delivery options. It’s lead products are the first subcutaneous formulations of furosemide (the most widely used parenteral diuretic in treating heart failure) and ceftriaxone (the most widely used parenteral antibiotic outside the hospital setting).
Sun Pharmaceutical Industries Ltd has informed BSE that one of the wholly owned subsidiaries of the company has acquired 13,000,000 Series B Preferred Stock ofscPharmaceuticals Inc. (equivalent to 14.58% fully diluted equity stake on conversion) by way of allotment. scPharmaceuticals Inc., is a United States pharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery.